DrScott Silliman

Avalon Intensive Outpatient Program

Symptomatic Carotid Outcomes Registry with multi-center Evaluation (SCORE) study

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard-of-Care Study of n-Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Acute Ischemic Stroke in Adult Subjects

A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720)

A multicenter, global, retrospective, observational study to characterize real-world clinical outcomes in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®) (EFFECT)

A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS 986141 for the Prevention of Recurrent Brain Infarction in Subjects Receiving acetylsalicylic acid (ASA) following Ischemic Stroke or Transient Ischemic Attack.

A LONG TERM FOLLOW UP STUDY FOR MULTIPLE SCLEROSIS PATIENTS WHO HAVE COMPLETED THE ALEMTUZUMAB EXTENSION STUDY

A MULTICENTER GLOBAL OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION

A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGTHS...

A PLACEBO CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THEEFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECT

A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THEEFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) . . .

GLYBURIDE ADVANTAGE IN MALIGNANT EDEMA AND STROKE

A RANDOMISED DOUBLE-BLIND MULTINATIONAL STUDY TO PREVENT VASCULAR EVENTS WITH TICAGRELOR COMPARED TO ASPIRIN...

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED VARIABLE TREATMENT DURATION STUDY...

Futility study of Deferoxamine Mesylate in intracerebral hemorrhage (Hi-Def Trial)Prime Aware No. 1U

A SINGLE ARM. OPENLABEL MUTICENTER STUDY EVALUATING THE LONGTERM SAFETY TOLERABIITY AND EFFICACY OF 0.5MG FINGOLIMOD

A MULTICENTER OBSERVATIONAL OPEN LABEL SINGLE ARM STUDY OF TYSABRI IN EARLY RELAPSING REMITTING MULTIPLE SCLEROSIS IN ..

A 12 MONTH RANDOMIZED RATER AND DOSE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FINGOLIMOD 0.25MG ....

Platelet-Oriented Inhibition in New TIA and Minor Ishemic Stroke (POINT) Trial, a RDMZ/DBLD, Multicenter Clinical Trial

JVC ANTIBODY PROGRAM IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING OR CONSIDERING TREATMENT WITH TYSABRI

A 6 MONTH RANDOMIZED ACTIVE COMPARATOR OPEN LABEL MULTICENTER STUDY TO EVALUATE PATIENT OUTCOMES SAFETY AND...

AN EXTENSION PROTOCOL FOR MULTIPLE SCLEROSIS PATIENTS WHO PARTICIPATED IN GENZYME-SPONSORED STUDIES OF ALEMTUZUMAB